Robotic Assisted Balance and Exoskeleton Training (REACTION) in Neurorehabilitation: a Feasibility Study
Launched by ROESSINGH RESEARCH AND DEVELOPMENT · Jan 27, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The REACTION trial is exploring a new robotic system designed to help people who have had a stroke or spinal cord injury improve their walking speed and balance. This study aims to understand how effective this technology can be for individuals with these neurological conditions. If you or a loved one is interested in participating, you need to be over 16 years old and able to give consent. For stroke patients, you should have had your first stroke and be able to walk with some assistance, while spinal cord injury patients must have specific types of injuries and also be able to walk independently.
During the study, participants will take part in two sessions that include walking and balance tasks, followed by an interview to share their experiences. It’s important to be aware that some individuals may not qualify for the study due to certain medical conditions or language barriers. The trial is not yet recruiting participants, but it aims to gather valuable information about the potential benefits of robotic assistance in rehabilitation.
Gender
ALL
Eligibility criteria
- In order to be eligible to participate in this study, a participant must meet all of the following criteria:
- • Age \> 16 years
- • Able to give informed consent
- Stroke patients:
- • first-ever ischemic or haemorrhagic stroke
- • FAC score between 3 and 4
- • (Sub)acute or chronic phase
- SCI patients:
- • Neurological injury levels ranging from C5 to T9
- • Motor incomplete spinal cord injury (ASIA impairment score of C or D)
- • Able to walk independently (without physical support)
- Exclusion Criteria:
- A potential participant who meets any of the following criteria will be excluded from participation in this study:
- • Premorbid disability of lower extremity
- • Progressive neurological diseases like dementia or Parkinson
- • Skin lesions or severely impaired sensation at the hemiparetic leg
- • Contraindication for mobilization, like lower limb fracture
- • Insufficient knowledge of the Dutch language to understand the purpose or meth-ods of the study
- • Pregnancy
About Roessingh Research And Development
Roessingh Research and Development (RRD) is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and technological solutions. Based in the Netherlands, RRD specializes in the development of rehabilitation technologies and evidence-based interventions aimed at improving patient outcomes. The organization collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials, ensuring that new therapies are rigorously tested and validated. With a strong commitment to enhancing quality of life for individuals with mobility and functional impairments, RRD stands at the forefront of research that bridges the gap between scientific discovery and practical application in clinical settings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Enschede, , Netherlands
Ubbergen, , Netherlands
Enscede, , Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported